Lakefront Biotherapeutics (LKFT) Net Income Growth (1y) (2015 - 2026)
Lakefront Biotherapeutics (LKFT) Net Income Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 1,228.66% |
| 10 | Lakefront Biotherapeutics | 1.86 Bn | -1.54 Bn | 1.91 Mn | -47.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.30% |
| Dec 31, 2025 | -105.55% |
| Sep 30, 2025 | 201.24% |
| Jun 30, 2025 | -130.02% |
| Mar 31, 2025 | -98.28% |
| Dec 31, 2024 | -96.87% |
| Sep 30, 2024 | 89.48% |
| Jun 30, 2024 | 260.93% |
| Mar 31, 2024 | 93.93% |
| Dec 31, 2023 | 394.75% |
| Sep 30, 2023 | 51.99% |
| Jun 30, 2023 | 101.59% |
| Mar 31, 2023 | 448.83% |
| Dec 31, 2022 | -2,304.90% |
| Sep 30, 2022 | 76.06% |
| Jun 30, 2022 | -440.58% |
| Mar 31, 2022 | -201.39% |
| Dec 31, 2021 | 101.72% |
| Sep 30, 2021 | 5.53% |
| Jun 30, 2021 | -89.74% |